In one of the most technologically sophisticated collaborations of recent times, Phoenix, a provider of DePIN AI infrastructure powering next-gen apps, has partnered with Tandem AI, a cutting-edge AI and physics-based platform for integrated drug discovery. The partnership will primarily result in Phoenix deploying TandemViz on Phoenix’s AI compute layer, SkyNet.
As a next-gen discovery platform, TandemViz empowers teams with intuitive interfaces that integrate access to battle-tested physics-based and AI in-silico drug design software with tools that streamline, manage, and analyze wet lab results. On the other hand, the SkyNet AI Elastic Compute Layer, from Phoenix, serves as a decentralized infrastructure for the full AI compute lifecycle, from training and inference to scaling and one-click deployment of AI models and their applications.
The benefits of AI drug discovery are revolutionizing, to say the least. Owing to the vast chemical space it dabbles in and the presence of millions and millions of molecules in that space, drug development could be a time-consuming and expensive process. AI drug discovery helps to get rid of these bottlenecks by recognizing hit and lead compounds and providing a quicker validation of the drug target and optimization of the drug structure design.
Now that the partnership will enable a custom lightweight version of the platform to run on SkyNet’s AI node network, it will become available to smaller organizations, independent researchers, and labs. Otherwise, AI drug discovery models – computationally intensive and high-cost – could only be accessed by resourceful large corporations.
Phoenix’s AI Elastic Compute Layer is compatible with both open-source and proprietary AI frameworks. It is, therefore, best positioned to cater to a spectrum of end-use applications for Tandem’s solution. Tandem, a company with over 350 employees, includes more than 50 award-winning AI and computational chemist scientists. With over 80 large pharmaceutical clients worldwide, it was founded by industry veteran Lanny Sun, who previously established Silicon Therapeutics.
If looked at from a wider perspective, the collaboration also opens up new horizons to the burgeoning DeSci (decentralized science) space. The DeSci players would now offer greater value, and decentralized architecture would be recognized even more for its potential.
